Format

Send to

Choose Destination
Alzheimers Dement (Amst). 2019 Jul 31;11:538-549. doi: 10.1016/j.dadm.2019.04.010. eCollection 2019 Dec.

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND).

Author information

1
Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
2
German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Magdeburg, Germany.
3
Institute of Cognitive Neuroscience, University College London, London, UK.
4
Center for Behavioral Brain Science, Magdeburg, Germany.
5
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, University College London, London, UK.
6
7Lund University BioImaging Center, Lund University, Lund, Sweden.
7
Department of Neurology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
8
Departement of Radiology, Sahlgrenska Akademy, University of Gothenburg, Gothenburg, Sweden.
9
NeuroSpin, CEA & Université Paris-Saclay, Gif-Sur-Yvette, France.
10
Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK.
11
Department of Radiology, University Medical Center Leiden, Leiden, The Netherlands.
12
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
13
Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK.
14
Imago 7 Research Foundation, Pisa, Italy.
15
Laboratory of Medical Physics and Magnetic Resonance, IRCCS Stella Maris, Pisa, Italy.
16
Center for Magnetic Resonance in Biology and Medicine (UMR 7339), CRMBM, CNRS - Aix Marseille Université, Marseille, France.
17
Physikalisch-Technische Bundesanstalt (PTB), Berlin, Germany.
18
Memory Clinic, Skåne University Hospital, Malmö, Sweden.
19
Erwin L. Hahn Institute for Magnetic Resonance Imaging, University of Duisburg-Essen, Essen, Germany.
20
Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
21
Faculty of Physics and Astronomy and Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
22
Danish Center for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
23
Department of Neurology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.
24
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
25
Center for Neuroscience Imaging Research, Institute for Basic Science and Department of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.
26
Techna Institute & Koerner Scientist in MR Imaging, University Health Network, Toronto, Ontario, Canada.
27
Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany.
28
Leibniz-Institute for Neurobiology (LIN), Magdeburg, Germany.

Abstract

Introduction:

The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists.

Methods:

EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization.

Results:

The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials.

Discussion:

The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.

KEYWORDS:

Alzheimer's disease (AD); Magnetic resonance imaging (MRI); Mild cognitive impairment (MCI); Parkinson's disease (PD); Subjective cognitive decline (SCD); Ultrahigh-field MRI; Vascular dementia

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center